BioSpace News Archive

ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, today announced that David Lockhart, CEO, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 5:30 p.m. ET on Wednesday, January 13, 2021.

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2020.

- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today issued a Letter to Shareholders from Spiros Jamas, Sc.D, its newly appointed Chief Executive Officer and a member of its Board of Directors.

Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, announced that long-time employee, Dr. Paul VanVeldhuisen, has been named President of Emmes Public Sector.

Sun Nuclear Corporation announced that its SunCHECK™ Quality Management Platform user base now exceeds 1,000 users globally in nearly 60 countries.

NuProbe, a genomics and molecular diagnostics company specialized in ultrasensitive sequencing panels, announces the closing of its oversubscribed $42M fundraising. The lead investors for this financing round are BioTrack Capital and Yonghua Capital.

Clinical Genomics (“CG” or the “Company”), a provider of cancer diagnostic solutions, including liquid biopsy tests, today announced that the New York State Department of Health (“NYSDOH”) has issued a permit to enable New York patients to access COLVERA, the Company’s liquid biopsy test designed to detect residual and recurrent disease in colorectal cancer (“CRC”).

Leukocare AG, a German biotechnology company specialized in formulation development for biologics, viral vectors and vaccines, announced the opening of its development laboratories and offices in Milford, MA, USA.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today provided a business update reviewing 2020 achievements and outlining the Company’s key business objectives for 2021

Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer, will present a company overview on Thursday, January 14, 2021 at 5:20 p.m.